EGFR and non-small cell lung carcinoma: Despite the development of advanced techniques in surgery, radiotherapy, and chemotherapy, anomalies such as the mutations or amplification of epidermal growth factor receptor (EGFR), mutation of Kirsten rat sarcoma viral oncogene homolog (KRAS), and high expression levels of multidrug transporters remain a major problem in the treatment of NSCLC [3].